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http://dx.doi.org/10.1016/j.jmii.2013Background: Serratia marcescens is an important nosocomial pathogen and the
characteristic property of resistance conferred by extended-spectrum beta-lactamase or a
novel AmpC cephalosporinase was not unusual in Taiwan. This study investigated
the trends in antimicrobial resistance in S. marcescens from a nationwide surveillance in
Taiwan.
Materials and methods: S.marcescens isolateswere collected biennially between 2002 and 2010
from medical centers and regional hospitals throughout Taiwan, as part of the Taiwan Surveil-
lance of Antimicrobial Resistance program. Minimal inhibitory concentrations were determined
by the Clinical and Laboratory Standards Institute reference broth microdilution method.
Results: A total of 403 nonduplicate S. marcescens isolates were collected, mostly from respi-
ratory samples (157, 39.0%), followed by the urinary tract samples (90, 22.3%). Overall, 99.3%
isolates were susceptible to imipenem, 93.8% to ceftazidime, 89.2% to minocycline, 87.8% to
amikacin, 86.8% to cefepime, 82.9% to aztreonam, 73.2% to ceftriaxone, 72.7% to levofloxacin,
63.8% to ciprofloxacin, 60.8% to trimethoprim/sulfamethoxazole (TMP/SMX), and 59.6% to
gentamicin. A significantly increased susceptibility rate after 2004 was observed for the
following antibiotics: amikacin (73.8% vs. 97.1%), gentamicin (40.0% vs. 72.4%), ciprofloxacinfectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Number 201, Section 2,
.tw (Y.-T. Lin).
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388 B.-H. Liou et al.(53.8% vs. 70.4%), ceftriaxone (53.8% vs. 86.0%), cefepime (74.4% vs. 95.1%), aztreonam (72.5%
vs. 89.7%), and TMP/SMX (41.3% vs. 73.7%).
Conclusion: In this 8-year study, the susceptibility of S. marcescens to ceftazidime and imipe-
nem remained consistently high in Taiwan. S. marcescens isolates demonstrated relatively
higher resistance to ciprofloxacin and levofloxacin, and therefore continued surveillance of
antimicrobial resistance, especially for fluoroquinolone, is warranted.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Serratia species are identified as aerobic, motile Gram-
negative rods, which occupy various habitats (mainly
water, plants, and soil). Human infections by members of
the genus Serratia were not well recognized until the
latter half of the 20th century.1 Serratia marcescens ac-
counts for the majority of isolates and appears to be a
pathogen capable of causing a wide spectrum of clinical
diseases, including wound infections, urinary tract in-
fections, pneumonia, central nervous system infections
such as meningitis, and bloodstream infections.1e6
Although S. marcescens is a rare cause of community-
acquired infections, it has emerged as an important
nosocomial pathogen that has been cultured from a va-
riety of sources, including disinfectants,7e9 pressure
transducers,10 bronchoscopes,11 and multidose medica-
tion vials.12 Factors such as debilitating clinical condition,
lengthy ward stay, exposure to medical interventions, and
increased frequency and intensity of direct contact with
staff hands predispose patients to S. marcescens infec-
tion. S. marcescens isolates account for 12.6% of noso-
comial urinary tract infection and resulted in 4.86%
fatality in a single institute in Taiwan.13 Although S.
marcescens has a relatively low virulence, it often causes
nosocomial infections in severely immunocompromised or
critically ill patients.1,2 The mortality rate of S. marces-
cens bacteremia was approximately 40e50% in previous
studies.14,15
S. marcescens is usually resistant to ampicillin, amoxi-
cillin, amoxicillin/clavulanate, ampicillin/sulbactam,
narrow-spectrum cephalosporins, cefuroxime, cepha-
mycins, nitrofurantoin, and colistin.1,16e18 S. marcescens
also harbors a chromosomal ampC gene that can extend
resistance to several more b-lactam antibiotics.1 In a
nationwide surveillance of antimicrobial resistance from
Taiwan in 2000, over half (52%) of S. marcescens were
resistant to ciprofloxacin, 48%, 24%, and 23% were resistant
to cefotaxime, aztreonam, and cefepime, respectively.19
However, many studies in recent years suggested that the
occurrence of extended-spectrum beta-lactamase (ESBL)-
producing isolates of S. marcescens was not unusual in
Taiwan.17,18,20e22 In addition, an institutional prolonged
spread of clonally related S. marcescens isolates with a
novel AmpC cephalosporinase (S4) that confers a phenotype
of resistance to cefotaxime was identified.23 Therefore,
continuous and extensive surveillance of the antimicrobial
resistance among S. marcescens isolates is necessary in
Taiwan. The aim of this study was to investigate the trendsin antimicrobial resistance in S. marcescens from a
nationwide surveillance in Taiwan.Materials and methods
Isolate collection and identification
S. marcescens isolates were collected biennially between
2002 and 2010, corresponding to periods IIIeVII of the
Taiwan Surveillance of Antimicrobial Resistance (TSAR)
program, from medical centers and regional hospitals
throughout Taiwan. In 2002, 2004, 2008, and 2010, isolates
were collected between July and September from the same
26 hospitals, except that isolates in 2006 were from 25
hospitals.24,25 These hospitals comprised 11 medical cen-
ters and 15 regional hospitals, which are located in all four
regions of Taiwan, namely seven, eight, eight, and three
hospitals in the north, central, south, and east regions,
respectively. Details of the collection process of the TSAR
program have been described previously.19,24,25 Each
isolate was subcultured onto the appropriate agar plates
(BBL; Becton Dickinson Microbiology Systems, Cockeysville,
MD, USA) to check for purity. S. marcescens was identified
by standard conventional biochemical tests followed by
confirmation with the VITEK Gram-negative Identification
plus cards (bioMe´rieux VITEK, Hazelwood, MO, USA), and
analytical profile index (API) 20E or API 32GN (bioMe´rieux,
Marcy-l’Etoile, France).
Antimicrobial susceptibility testing
Antimicrobial susceptibility was determined by the
reference broth microdilution method using freshly pre-
pared cation-adjusted Mu¨ellereHinton broth and
following the criteria proposed by the Clinical and Labo-
ratory Standards Institute (CLSI).26 Minimum inhibitory
concentration (MIC) interpretive criteria were defined by
the CLSI guidelines for all drugs except tigecycline, for
which the U.S. Food and Drug Administration breakpoints
were used.
Statistical analyses
All analyses were performed with SPSS version 19.0 (SPSS
Inc., Chicago, IL, USA). Significance of differences in fre-
quencies and proportions were tested by Pearson c2 test,
and p  0.05 was considered to be statically significant.
Table 1 Source breakdown of 403 Serratia marcescens isolates by year, hospital type, geographic region, specimen type, and
patient location
Source category Number (% of source category) of isolates from each year
TSAR III (2002) IV (2004) V (2006) VI (2008) VII (2010) Total
Total 95 65 71 88 84 403
Hospital type
Medical center 33 (34.7) 35 (53.8) 32 (45.1) 39 (44.3) 38 (45.2) 177 (43.9)
Regional hospital 62 (65.3) 30 (46.2) 39 (54.9) 49 (55.7) 46 (54.8) 226 (56.1)
Region of Taiwan
Northern 34 (35.8) 17 (26.2) 24 (33.8) 41 (46.6) 38 (45.2) 154 (38.2)
Central 28 (29.5) 29 (44.6) 21 (29.6) 31 (35.2) 23 (27.4) 132 (32.8)
Southern 18 (18.9) 16 (24.6) 22 (31.0) 14 (15.9) 20 (23.8) 90 (22.3)
Eastern 15 (15.8) 3 (4.6) 4 (5.6) 2 (2.3) 3 (3.6) 27 (6.7)
Specimen type
Blood 20 (21.1) 10 (15.4) 8 (11.3) 19 (21.6) 20 (23.8) 77 (19.1)
Respiratory tract 29 (30.5) 19 (29.2) 32 (45.1) 39 (44.3) 38 (45.2) 157 (39.0)
Urine 31 (32.6) 21 (32.3) 19 (26.8) 10 (11.4) 9 (10.7) 90 (22.3)
Pus/abscess/wound 12 (12.6) 15 (23.1) 7 (9.9) 12 (13.6) 12 (14.3) 58 (14.4)
Othersa 3 (3.2) 0 (0.0) 5 (7.0) 8 (9.1) 5 (6.0) 21 (5.2)
Patient location
ICU inpatient 18 (18.9) 13 (20.0) 22 (31.0) 19 (21.6) 21 (25.0) 93 (23.1)
Non-ICU inpatientb 68 (71.6) 38 (58.5) 34 (47.9) 57 (64.8) 55 (65.5) 252 (62.5)
OPD/ER 9 (9.5) 14 (21.5) 15 (21.1) 12 (13.6) 8 (9.5) 58 (14.4)
a Others: one from ascites, one from joints, two from bile, four from ears, seven from catheter tips, four from eyes/conjunctiva/
corneas, one from urethra, and one from discharge.
b Included six isolates from respiratory care center/respiratory care ward.
ER Z emergency room; ICU Z intensive care unit; OPD Z outpatient department; TSAR Z Taiwan Surveillance of Antimicrobial
Resistance program.
Data are presented as n (%).
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A total of 403 nonduplicate S. marcescens isolates were
identified and tested for susceptibility during the 8-year
study period of 2002e2010. Table 1 summarizes the
source breakdown of the 403 isolates from each run of
TSAR. Isolates were mostly recovered from respiratory
samples (157 isolates, 39.0%), followed by the urinary tract
(90, 22.3%), and blood (77, 19.1%). Most isolates (345,
85.6%) were from inpatients, including 93 (23.1%) from the
intensive care unit (ICU) and 252 (62.5%) from non-ICU
patients. Isolates from northern Taiwan comprised the
largest proportion (154, 38.2%). Among the 390 isolates
whose patient age was known, the mean age was
65.4  20.5 years and 60.25% were from those aged 65
years.
The in vitro susceptibilities, MIC50, MIC90 (MIC at which
50% and 90% of isolates were inhibited), and MIC range of
the isolates to various antimicrobial agents are shown in
Table 2. Overall, 99.3% of isolates were susceptible to
imipenem, 93.8% to ceftazidime, 86.0% to piperacillin/
tazobactam, 72.7% to levofloxacin, 63.8% to ciprofloxacin,
60.8% to trimethoprim/sulfamethoxazole (TMP/SMX), and
59.6% to gentamicin according to the CLSI criteria. By
contrast, susceptibility of 10% for each round of TSAR was
observed for ampicillin, amoxicillin/clavulanate, cefazolin,
cefoxitin, cefuroxime, and tetracycline. The MIC50 and
MIC90 of tigecycline were 0.5 mg/mL and 1 mg/mL, respec-
tively. The susceptibility rate of S. marcescens fromdifferent patient locations was compared (Table 3). Isolates
from the ICU had higher rates of nonsusceptibility than
isolates from other locations for amikacin, gentamicin,
ciprofloxacin, levofloxacin, ceftazidime, cefepime, and
TMP/SMX, but the differences were not significant. The
susceptibility rate to ciprofloxacin/levofloxacin was lower
in northern Taiwan than other regions (p Z 0.025 and
p Z 0.002, respectively).
Fig. 1 illustrates the comparison of susceptibility rate for
selected antibiotics from different specimen sources. We
found that isolates from urine had the lowest susceptibility
rate for the various antibiotics. Isolates from urine were
significantly less susceptible than those from nonurine
sources for amikacin (64.4% vs. 94.6%, p < 0.001), genta-
micin (38.9% vs. 65.5%, p < 0.001), ciprofloxacin (46.7% vs.
68.7%, p < 0.001), ceftriaxone (41.1% vs. 82.4%, p < 0.001),
cefepime (65.6% vs. 93.0%, p < 0.001), aztreonam (61.1%
vs. 89.1%, p < 0.001), and TMP/SMX (37.8% vs. 67.4%,
p < 0.001). Trends in susceptibility of S. marcescens to
various antibiotics over 8 years are demonstrated in Fig. 2.
S. marcescens remained consistently highly susceptible to
imipenem and ceftazidime throughout the study period. A
significantly increased susceptibility rate after 2004 was
observed for the following antibiotics: amikacin (73.8% vs.
97.1%, p < 0.001), gentamicin (40.0% vs. 72.4%, p < 0.001),
ciprofloxacin (53.8% vs. 70.4%, p Z 0.001), ceftriaxone
(53.8% vs. 86.0%, p < 0.001), cefepime (74.4% vs. 95.1%,
p < 0.001), aztreonam (72.5% vs. 89.7%, p < 0.001), and
TMP/SMX (41.3% vs. 73.7%, p < 0.001).
Table 2 MICs and susceptible percentage of Serratia marcescens isolates
Antimicrobial agent TSAR MIC (mcg/mL) % of isolates
MIC50 MIC90 Range Susceptible
Amikacin IIIeVII 4 >32 2e>32 87.8
Gentamicin IIIeVII 1 >8 0.5e>8 59.6
Ciprofloxacin IIIeVII 0.5 >2 0.03e6 63.8
Levofloxacina VIeVII 1 4 0.5e>8 72.7
Ceftazidime IIIeVII 1 4 0.5e>16 93.8
Ceftriaxone IIIeVII 2 >32 0.5e>32 73.2
Cefepime IIIeVII 1 >16 0.5e>16 86.8
Aztreonam IIIeVII 2 >16 1e>16 82.9
Imipenem IIIeVII 1 2 0.25e>8 99.3
TMP/SMX IIIeVII 0.5 4 0.5e>4 60.8
Piperacillin
/Tazobactamb
VeVII 8 32 4e>64 86.0
Tigecyclinea VIeVII 0.5 1 0.25e2 98.8
a Isolates during 2008e2010 Z 172.
b Isolates during 2006e2010 Z 243.
MIC Z minimum inhibitory concentration; MIC50 and MIC90 Z MIC at which 50% and 90% of isolates were inhibited; TMP/
SMX Z trimethoprim/sulfamethoxazole; TSAR Z Taiwan Surveillance of Antimicrobial Resistance program.
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In the present study, we examined trends in susceptibility
to multiple antibiotics for 403 nonduplicate clinical S.
marcescens isolates in Taiwan between 2002 and 2010. The
results show that the activities of ceftazidime and imipe-
nem have remained consistently high over the years. Sus-
ceptibilities of 10% for each round of TSAR were observed
for ampicillin, amoxicillin/clavulanate, cefazolin, cefox-
itin, cefuroxime, and tetracycline. FluoroquinolonesTable 3 Comparison of Serratia marcescens susceptibility
among isolates from different patient locations and spec-
imen types
Antimicrobial
agent
Patient location p
Non-ICU
(n Z 252)
ICU
(n Z 93)
OPD/ER
(n Z 58)
S S S
Amikacin 88.5 83.9 91.4 0.334
Gentamicin 60.3 54.8 63.8 0.531
Ciprofloxacin 64.3 61.3 65.5 0.849
Levofloxacin 74.1 70.7 72.7 0.841
Ceftazidime 94.0 92.5 94.8 0.803
Ceftriaxone 75.0 73.1 65.5 0.343
Cefepime 87.7 82.8 89.7 0.395
Aztreonam 85.3 75.3 84.5 0.086
Imipenem 98.8 100 100 0.433
TMP/SMX 60.3 59.1 65.5 0.727
Piperacillin
/Tazobactam
89.7 82.3 86.0 0.082
Data are presented as %.
ER Z emergency room; ICU Z intensive care unit;
OPD Z outpatient department; S Z susceptible; TMP/
SMX Z trimethoprim/sulfamethoxazole.showed less activity against S. marcescens than other b-
lactams.
In Taiwan, the occurrence of CTX-M-3 ESBL-producing
isolates of S. marcescens was not unusual,17,18,20e22 and the
novel AmpC cephalosporinase (S4) was reported previ-
ously.23 The distinctive property of resistance to cefotax-
ime but not ceftazidime was due to CTX-M-3 ESBL and SRT-
like AmpC such as S4 conferring the same phenotype of
resistance to cefotaxime. The antibiogram-based method
to simplify the screening of potential ESBL-producing pop-
ulations among S. marcescens isolates has also been re-
ported recently.22 Although the molecular characteristics
of isolates were lacking in the current study, the higher
susceptibility of ceftazidime than ceftriaxone corre-
sponded to the previous studies,17,18,20e23 and further
underlined the need to establish practical guidelines for
ESBL screening, confirmation, and reporting for chromo-
somal AmpC producers in Taiwan.21
In the Tigecycline Evaluation and Surveillance Trial
study, 4857 isolates of S. marcescens collected globally
between 2004 and 2007 with susceptibilities  90% were
observed for amikacin, levofloxacin, ceftazidime, cefe-
pime, imipenem, meropenem, piperacillin/tazobactam,
and tigecycline.27 A similar study conducted by Hawser et al
collected 753 clinical isolates of S. marcescens throughout
the AsiaePacific region between 2004 and 2010 and
demonstrated constantly high susceptibility to levofloxacin
(84e97%).28 A characteristic finding in the present study
was the much lower susceptibility to levofloxacin and cef-
triaxone compared with the global data. Susceptibility to
levofloxacin in the current study was only tested between
2008 and 2010, but susceptibility to ciprofloxacin was
tested throughout the study period. The much lower sus-
ceptibility to ciprofloxacin suggests that resistance to flu-
oroquinolones is the major concern surrounding drug-
resistant S. marcescens in Taiwan. The susceptibility rate
to ceftriaxone was 55e85% between 2004 and 2010 in the
AsiaePacific region, which is consistent with our findings.
Figure 1. Comparison of susceptibility of Serratia marcescens to various antibiotics in different specimens. TSAR Z Taiwan
Surveillance of Antimicrobial Resistance program.
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to minocycline (decreased to 41e60% in 2008e2010) and
tigecycline in S. marcescens.28 By contrast, susceptibility to
minocycline and tigecycline tested in 2010 in the present
study showed higher susceptibility rates of 89.2% and
98.8%, respectively.
Shih et al found that 99% of S. marcescens blood isolates
in 1999e2003 were sensitive to ceftazidime, but only 19%
were sensitive to ciprofloxacin, 32% to levofloxacin, and
18% to TMP/SMX in a single institute in Taiwan.15 The high
susceptibility rate of ceftazidime is consistent with the
current study. A previous nationwide surveillance of anti-
microbial resistance among Enterobacteriaceae at the ICUs
of 10 major teaching hospitals in Taiwan in 2005 reported
low susceptibility of S. marcescens to ciprofloxacin (43%)
and levofloxacin (66%).29 Despite_ENREF_23 the present
study showing increased susceptibilities to ciprofloxacin
(64.3%) and levofloxacin (74.1%) compared with previous
results in Taiwan, the resistance to fluoroquinolones con-
tinues to be a problem in Taiwan.
Examination of trends in antimicrobial susceptibility has
revealed higher resistant rates for amikacin, gentamicin,Figure 2. Trends in susceptibility of Serratia mciprofloxacin, ceftriaxone, cefepime, aztreonam, and TMP/
SMX prior to 2004 than those after that date. The higher
proportion of isolates recovered from urine between 2002
and 2004 may have influenced the results. The significantly
higher proportion of isolates recovered from urine between
2002 and 2004 (32.5%) than that after 2004 (15.6%, p <
0.001) may have influenced the results. The reasons why
isolates from urine had the lowest susceptibility rate for
the various antibiotics cannot be clearly defined. It might
imply that we should put more focus on the resistance
pattern in the urinary isolates. In addition, after the
emergence of severe acute respiratory syndrome in 2003,
the reinforcement of prevention of health care-associated
infection in hospitals resulted in a more cautious
approach to intervention with antimicrobials as a part of
the infection control policy.30 The trends in total con-
sumption of aminoglycosides, extended-spectrum cepha-
losporins, and fluoroquinolones significantly increased prior
to 2004 and remained stable after 2004 in the hospital-wide
investigation.30,31 The reduced consumption of antibiotics
in Taiwan may explain the observation of greater suscep-
tibility after 2004 in the present study.arcescens to various antibiotics over 10 years.
392 B.-H. Liou et al.We recognize a number of potential biases in the present
study. The first limitation concerns the specimen types.
Isolates from the urinary tract showed higher resistance
rates to many antibiotics than those from other sites;
therefore, the higher percentage of urine specimen prior to
2004 may result in lower overall susceptibility in this
period. Second, <10% of isolates were collected from
eastern Taiwan and the data are likely to have under-
estimated the events occurring in this region. Third, we did
not analyze the resistant mechanism due to the lack of
molecular method such as multiplex polymerase chain re-
action screening of ampC genes in these S. marcescens
isolates. Finally, given the limited clinical information from
this surveillance, we cannot exactly determine the clinical
significance of these isolates.
In conclusion, the results of this study suggest that the
susceptibility of S. marcescens to ceftazidime and imipe-
nem in Taiwan remained consistently high over the study
period. S. marcescens isolates from Taiwan demonstrated
relatively higher resistance to ciprofloxacin and levo-
floxacin than other b-lactams, and continued surveillance
of antimicrobial resistance in S. marcescens, especially for
fluoroquinolones, is warranted. TSAR is ongoing in Taiwan
involving clinically important bacteria. The longitudinal
surveillance study will continue to provide key information
related to antimicrobial resistance over time.
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